We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$193M
AUM Growth
-$5.35M
Cap. Flow
-$8.43M
Cap. Flow %
-4.36%
Top 10 Hldgs %
99.1%
Holding
18
New
4
Increased
2
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$7.39M
2
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$1.19M
3
GLMD icon
Galmed Pharmaceuticals
GLMD
+$846K
4
NRX
NEPHROGENEX INC COM
NRX
+$510K
5
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$465K

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$15.1M
2
SQNM
SEQUENOM INC NEW
SQNM
+$2.07M
3
PRKR
Parkervision Inc
PRKR
+$730K
4
ECTE
ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE)
ECTE
+$52.1K

Sector Composition

Rank Sector Weight
1 Healthcare 23.61%
2 Technology 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$147M 75.94%
4,559,038
-409,164
-8% -$15.1M
AMPE
2
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$18.8M 9.74%
9,881
+3,124
+46% +$7.39M
ARCT icon
3
Arcturus Therapeutics
ARCT
$157M
$12.5M 6.45%
98,143
– –
TOVX icon
4
Theriva Biologics
TOVX
$10.2M
$3.5M 1.81%
155
– –
KERX
5
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$3.41M 1.76%
200,000
– –
LUMO
6
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.2M 1.14%
8,604
– –
NWBO
7
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$1.45M 0.75%
+200,300
New +$1.19M
INO icon
8
Inovio Pharmaceuticals
INO
$79.8M
$1.36M 0.7%
8,507
– –
MACK
9
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$809K 0.42%
20,410
+10,877
+114% +$465K
GLMD icon
10
Galmed Pharmaceuticals
GLMD
$3.94M
$746K 0.39%
+361
New +$846K
ADXS
11
DELISTED
Advaxis Inc
ADXS
$706K 0.37%
15,000
– –
NRX
12
DELISTED
NEPHROGENEX INC COM
NRX
$412K 0.21%
+50,000
New +$510K
PRKR
13
DELISTED
Parkervision Inc
PRKR
$240K 0.12%
5,000
-15,000
-75% -$730K
AKTX
14
Akari Therapeutics
AKTX
$15.2M
$151K 0.08%
+3
New +$170K
ADXSW
15
DELISTED
Advaxis Inc Warrants
ADXSW
$141K 0.07%
112,500
– –
ECTE
16
DELISTED
ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE)
ECTE
$86K 0.04%
28,630
-15,815
-36% -$52.1K
SQNM
17
DELISTED
SEQUENOM INC NEW
SQNM
– –
-893,600
Closed -$2.07M
VVUS
18
CALL
DELISTED
Vivus Inc
VVUS
– –
-500
Closed -$1.05M

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q1 2014 Portfolio in Review

As of Q1 2014, Knoll Capital Management held 18 positions worth $193M, down 2.7% from $199M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Knoll Capital Management withdrew a net $8.43M in Q1 2014, closing 2 positions and reducing 3 holdings. Its most notable exit was SEQUENOM INC NEW, an estimated $2.07M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 18% a quarter earlier, followed by Technology.

Against the trend, Knoll Capital Management opened a new position in Northwest Biotherapeutics, Inc. Common stock worth $1.45M.

  • Knoll Capital Management's largest Q1 2014 buy was Northwest Biotherapeutics, Inc. Common stock: 200,300 shares worth $1.45M.
  • Knoll Capital Management added most to Ampio Pharmaceuticals Inc. in Q1 2014, an estimated $7.39M increase.
  • Knoll Capital Management's biggest Q1 2014 reduction was MEDIVATION, INC., cutting an estimated $15.1M.
  • Knoll Capital Management fully exited SEQUENOM INC NEW in Q1 2014, selling an estimated $2.07M.
  • Knoll Capital Management's ten largest holdings make up 99% of its $193M portfolio in Q1 2014.
  • Knoll Capital Management opened 4 new positions and closed 2 in Q1 2014.
  • Knoll Capital Management's portfolio value fell 2.7% quarter-over-quarter to $193M.

Based on Knoll Capital Management's 13F filing for Q1 2014, filed 15 May 2014.